LyphoMed
Executive Summary
Shelf registration statement covering 1.5 mil. common shares filed with Securities & Exchange Commission. Proceeds will primarily be used to pay for recent Invenex and Bristoject acquisitions. In addition, Fujisawa will purchase 500,000 shares in a private transaction that will maintain its stake in LyphoMed at about 26.5%.